Skip to Content

Sarafem (fluoxetine) Disease Interactions

There are 12 disease interactions with Sarafem (fluoxetine):

Major

Ssri Antidepressants (Includes Sarafem) ↔ Depression

Severe Potential Hazard, Moderate plausibility

Applies to: Depression, Psychosis

Adult and pediatric patients with depression and other psychiatric disorders may experience worsening of their symptoms and may have the emergence of suicidal thoughts and behavior. Patients should be monitored appropriately and observed closely for worsening of their symptoms, suicidality or changes in their behavior, especially during the first few months of treatment, and at times of dose changes. Families and caregivers should be advised of the need for close observation and communication with the treating physician. Discontinuing the medication should be considered if symptoms are persistently worse, or abrupt in onset. It may be prudent to refrain from dispensing large quantities of medication to these patients.

Moderate

Fluoxetine (Includes Sarafem) ↔ Diabetes

Moderate Potential Hazard, Moderate plausibility

Applies to: Diabetes Mellitus

Fluoxetine may alter blood glucose control in patients with diabetes. Hypoglycemia may occur during therapy with fluoxetine, and hyperglycemia may occur following discontinuation of the drug. Dosage adjustments in insulin and/or oral hypoglycemic medications may be necessary in patients with diabetes whenever fluoxetine therapy is initiated or discontinued.

References

  1. "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
Moderate

Ssri (Includes Sarafem) ↔ Hyponatremia

Moderate Potential Hazard, Moderate plausibility

Applies to: Hyponatremia

Treatment with SSRI antidepressants can cause hyponatremia. Caution should be used when treating patients with hyponatremia or at greater risk of hyponatremia such as the elderly, patients taking diuretics or who are volume depleted.

Moderate

Ssris (Includes Sarafem) ↔ Glaucoma

Moderate Potential Hazard, Moderate plausibility

Applies to: Glaucoma (Narrow Angle)

Some SSRI antidepressants such as fluoxetine, paroxetine and sertraline may have an effect on pupil size causing dilation. This effect can potentially narrow the eye angle resulting in increased intraocular pressure and angle closure glaucoma, especially in predisposed patients. These drugs should be used with caution in patients with angle-closure glaucoma or history of glaucoma.

Moderate

Ssris (Includes Sarafem) ↔ Liver Disease

Moderate Potential Hazard, High plausibility

Applies to: Liver Disease

Selective serotonin reuptake inhibitors (SSRIs) are primarily metabolized by the liver. The plasma concentrations of SSRIs and their metabolites may be increased and the half-lives prolonged in patients with impaired hepatic function. Dosage adjustments may be necessary in accordance with the individual product package labeling.

References

  1. Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991): 952-61
  2. Finley PR "Selective serotonin reuptake inhibitors: pharmacologic profiles and potential therapeutic distinctions." Ann Pharmacother 28 (1994): 1359-69
  3. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.
  4. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.
  5. "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.
  6. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
  7. "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.
  8. Lund J, Thayssen P, Mengel H, Pedersen OL, Kristensen CB, Gram LF "Paroxetine: pharmacokinetics and cardiovascular effects after oral and intravenous single doses in man." Acta Pharmacol Toxicol (Copenh) 51 (1982): 351-7
  9. Benfield P, Ward A "Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness." Drugs 32 (1986): 313-34
  10. Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992): 604-24
  11. Kaye CM, Haddock RE, Langley PF, Mellows G, Tasker TC, Zussman BD, Greb WH "A review of the metabolism and pharmacokinetics of paroxetine in man." Acta Psychiatr Scand Suppl 350 (1989): 60-75
  12. Krastev Z, Terziivanov D, Vlahov V, Maleev A, Greb WH, Eckl KM, Dierdorf HD, Wolf D "The pharmacokinetics of paroxetine in patients with liver cirrhosis." Acta Psychiatr Scand Suppl 350 (1989): 91-2
  13. Schenker S, Bergstrom RF, Wolen RL, Lemberger L "Fluoxetine disposition and elimination in cirrhosis." Clin Pharmacol Ther 44 (1988): 353-9
  14. "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
  15. Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988): 46-51
  16. Wilde MI, Plosker GL, Benfield P "Fluvoxamine. An updated review of its pharmacology, and therapeutic use in depressive illness." Drugs 46 (1993): 895-924
  17. van Harten J "Clinical pharmacokinetics of selective serotonin reuptake inhibitors." Clin Pharmacokinet 24 (1993): 203-20
View all 17 references
Moderate

Ssris (Includes Sarafem) ↔ Mania

Moderate Potential Hazard, Moderate plausibility

Applies to: Mania, Bipolar Disorder, Depression

Selective serotonin reuptake inhibitors (SSRIs), like other antidepressants, may occasionally cause or activate mania or hypomania. The reported incidence ranged from 0.1% to 2% in premarketing testing of several SSRIs. Patients with bipolar disorder are generally more likely to experience mania from antidepressants. Therapy with SSRIs should be administered cautiously in patients with a history of mania or bipolar disorder. Prior to initiating treatment it is recommended to adequately screen patients for bipolar disorder, including a family history of suicide, bipolar disorder, and depression.

References

  1. Peet M "Induction of mania with selective serotonin re-uptake inhibitors and tricyclic antidepressants." Br J Psychiatry 164 (1994): 549-50
  2. Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991): 952-61
  3. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4
  4. "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.
  5. Burrai C, Bocchetta A, del Zompo M "Mania and fluvoxamine." Am J Psychiatry 148 (1991): 1263-4
  6. Piredda SG, Rubinstein SL "Hypomania induced by fluoxetine?" Biol Psychiatry 32 (1992): 107
  7. Vieta E, Bernardo M "Antidepressant-induced mania in obsessive-compulsive disorder." Am J Psychiatry 149 (1992): 1282-3
  8. Lensgraf SJ, Favazza AR "Antidepressant-induced mania." Am J Psychiatry 147 (1990): 1569
  9. Achamallah NS, Decker DH "Mania induced by fluoxetine in an adolescent patient." Am J Psychiatry 148 (1991): 1404
  10. Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992): 604-24
  11. Beal DM, Harris D, Bartos M, Korsak C, Splane G, Quant R, Starke J "Safety and efficacy of fluoxetine." Am J Psychiatry 148 (1991): 1751
  12. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.
  13. Howland RH "Induction of mania with serotonin reuptake inhibitors." J Clin Psychopharmacol 16 (1996): 425-7
  14. Laporta M, Chouinard G, Goldbloom D, Beauclair L "Hypomania induced by sertraline, a new serotonin reuptake inhibitor." Am J Psychiatry 144 (1987): 1513-4
  15. Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994): 387-95
  16. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
  17. Mundo E, Ronchi P, Bellodi L "Drug-induced mania." Hosp Community Psychiatry 44 (1993): 689-90
  18. Berthier ML, Kulisevsky J "Fluoxetine - induced mania in a patient with poststroke depression." Br J Psychiatry 163 (1993): 698-9
  19. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.
  20. Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995): 1238-9
  21. Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992): 61-6
  22. "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.
  23. Diaferia G, Mundo E, Bianchi Y, Ronchi P "Behavioral side effects in obsessive-compulsive patients treated with fluvoxamine: a clinical description." J Clin Psychopharmacol 14 (1994): 78-9
  24. Dorevitch A, Frankel Y, Bar-Halperin A, Aronzon R, Zilberman L "Fluvoxamine-associated manic behavior: a case series." Ann Pharmacother 27 (1993): 1455-7
  25. "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
  26. Jefferson JW, Greist JH, Perse TL, Rosenfeld R "Fluvoxamine-associated mania/hypomania in patients with obsessive- compulsive disorder." J Clin Psychopharmacol 11 (1991): 391-2
  27. Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30
View all 27 references
Moderate

Ssris (Includes Sarafem) ↔ Platelet Function

Moderate Potential Hazard, High plausibility

Applies to: Bleeding, Coagulation Defect, Thrombocytopathy, Thrombocytopenia, Vitamin K Deficiency

The use of selective serotonin reuptake inhibitors (SSRIs) has been associated with altered platelet function. Petechiae, purpura, ecchymosis, increased bleeding times, epistaxis and gastrointestinal hemorrhage have been reported. Therapy with SSRIs should be administered cautiously in patients with severe active bleeding or a hemorrhagic diathesis.

References

  1. "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.
  2. Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30
  3. Alderman CP, Moritz CK, Ben-Tovim DI "Abnormal platelet aggregation associated with fluoxetine therapy." Ann Pharmacother 26 (1992): 1517-9
  4. Hergovich N, Aigner M, Eichler HG, Entlicher J, Drucker C, Jilma B "Paroxetine decreases platelet serotonin storage and platelet function in human beings." Clin Pharmacol Ther 68 (2000): 435-42
  5. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
  6. "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.
  7. Leung M, Shore R "Fluvoxamine-associated bleeding." Can J Psychiatry 41 (1996): 604-5
  8. Pai VB, Kelly MW "Bruising associated with the use of fluoxetine." Ann Pharmacother 30 (1996): 786-8
  9. Krivy J, Wiener J "Sertraline and platelet counts in idiopathic thrombocytopenia purpura." Lancet 345 (1995): 132
  10. Ottervanger JP, Stricker BH, Huls J, Weeda JN "Bleeding attributed to the intake of paroxetine." Am J Psychiatry 151 (1994): 781-2
  11. Skop BP, Brown TM "Potential vascular and bleeding complications of treatment with selective serotonin reuptake inhibitors." Psychosomatics 37 (1996): 12-6
  12. Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30
  13. Aranth J, Lindberg C "Bleeding, a side effect of fluoxetine." Am J Psychiatry 149 (1992): 412
  14. Alderman CP, Seshadri P, Ben-Tovim DI "Effects of serotonin reuptake inhibitors on hemostasis." Ann Pharmacother 30 (1996): 1232-4
  15. "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
  16. Yaryura-Tobias JA, Kirschen H, Ninan P, Mosberg HJ "Fluoxetine and bleeding in obsessive-compulsive disorder." Am J Psychiatry 148 (1991): 949
  17. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.
  18. Humphries JE, Wheby MS, VandenBerg SR "Fluoxetine and the bleeding time." Arch Pathol Lab Med 114 (1990): 727-8
View all 18 references
Moderate

Ssris (Includes Sarafem) ↔ Qt Prolongation

Moderate Potential Hazard, Moderate plausibility

Applies to: Long QT Syndrome, Ventricular Arrhythmia

Some SSRI antidepressants such as fluoxetine and citalopram have shown to cause QT interval prolongation and ventricular arrhythmias including Torsade de Pointes. These drugs should be used with caution in patients with congenital QT syndrome, a previous personal or family history of QT prolongation, and ventricular arrhythmia. Consider periodic EKG assessment on these patients. Treatment should be discontinued and a cardiac evaluation should be considered if a patient develops signs or symptoms of ventricular arrhythmia.

Moderate

Ssris (Includes Sarafem) ↔ Seizure Disorders

Moderate Potential Hazard, Moderate plausibility

Applies to: Seizures

Selective serotonin reuptake inhibitors (SSRIs) may trigger seizures in approximately 0.2% of patients, and some of them are not recommended in patients with unstable epilepsy. Therapy with SSRIs should be administered cautiously in patients with seizure disorders.

References

  1. Marshall RD, Printz D, Cardenas D, Abbate L, Liebowitz MR "Adverse events in PTSD patients taking fluoxetine." Am J Psychiatry 152 (1995): 1238-9
  2. Hargrave R, Martinez D, Bernstein AJ "Fluoxetine-induced seizures." Psychosomatics 33 (1992): 236-9
  3. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.
  4. Messiha FS "Fluoxetine - adverse effects and drug-drug interactions." J Toxicol Clin Toxicol 31 (1993): 603-30
  5. Nemeroff CB "The clinical pharmacology and use of paroxetine, a new selective serotonin reuptake inhibitor." Pharmacotherapy 14 (1994): 127-38
  6. "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.
  7. "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
  8. Kim KY, Craig JM, Hawley JM "Seizure possibly associated with fluvoxamine." Ann Pharmacother 34 (2000): 1276-8
  9. Edwards JG, Inman WH, Wilton L, Pearce GL "Prescription-event monitoring of 10,401 patients treated with fluvoxamine." Br J Psychiatry 164 (1994): 387-95
  10. Levine R, Kenin M, Hoffman JS, Dayknepple E "Grand mal seizures associated with the use of fluoxetine." J Clin Psychopharmacol 14 (1994): 145-6
  11. Boyer WF, Blumhardt CL "The safety profile of paroxetine." J Clin Psychiatry 53 Suppl (1992): 61-6
  12. Madi L, Obrien AAJ, Fennell J "Status epilepticus secondary to fluoxetine." Postgrad Med J 70 (1994): 383-4
  13. Murdoch D, McTavish D "Sertraline. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in depression and obsessive- compulsive disorder." Drugs 44 (1992): 604-24
  14. Doogan DP, Caillard V "Sertraline: a new antidepressant." J Clin Psychiatry 49 (1988): 46-51
  15. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
  16. Guthrie SK "Sertraline: a new specific serotonin reuptake blocker." DICP 25 (1991): 952-61
  17. Spivey KM, Wait CM "Perioperative seizures and fluvoxamine." Br J Anaesth 71 (1993): 321
  18. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.
  19. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4
  20. "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.
  21. Deahl M, Trimble M "Serotonin reuptake inhibitors, epilepsy and myoclonus." Br J Psychiatry 159 (1991): 433-5
View all 21 references
Moderate

Ssris (Includes Sarafem) ↔ Siadh

Moderate Potential Hazard, Moderate plausibility

Applies to: Dehydration, Hyponatremia, SIADH

The use of selective serotonin reuptake inhibitors (SSRIs) has rarely been associated with hyponatremia, sometimes secondary to development of the syndrome of inappropriate secretion of antidiuretic hormone (SIADH). These events have generally been reversible following discontinuation of SSRI therapy and/or medical intervention. SSRI-related hyponatremia may be more common in elderly female patients and those who are volume-depleted or receiving concomitant diuretic therapy. Caution may be warranted when SSRI therapy is administered in these patients and patients with preexisting hyponatremia or SIADH. Serum electrolytes, especially sodium as well as BUN and plasma creatinine, should be monitored regularly.

References

  1. Kessler J, Samuels SC "Sertraline and hyponatremia." N Engl J Med 335 (1996): 524
  2. Schattner A, Skurnik Y "Fluoxetine-induced SIADH." J Am Geriatr Soc 44 (1996): 1413
  3. Baliga RR, McHardy KC "Syndrome of inappropriate antidiuretic hormone secretion due to fluvoxamine therapy [published erratum appears in Br J Clin Pract 1993 May-Jun;47(3):119]." Br J Clin Pract 47 (1993): 62-3
  4. Settle EC "Antidepressant drugs: disturbing and potentially dangerous adverse effects." J Clin Psychiatry 59 Suppl 16 (1998): 25-30
  5. Robinson D, Brooks J, Mahler E, Sheikh JI "SIADH--compulsive drinking or SSRI influence?" Ann Pharmacother 30 (1996): 885
  6. "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.
  7. Cohen BJ, Mahelsky M, Adler L "More cases of SIADH with fluoxetine." Am J Psychiatry 147 (1990): 948-9
  8. Woo MH, Smythe MA "Association of SIADH with selective serotonin reuptake inhibitors." Ann Pharmacother 31 (1997): 108-10
  9. Chua TP, Vong SK "Hyponatraemia associated with paroxetine." BMJ 306 (1993): 143
  10. Ayonrinde OT, Reutens SG, Sanfilippo FM "Paroxetine-induced SIADH." Med J Aust 163 (1995): 390
  11. Doshi D, Borison R "Association of transient SIADH with sertraline." Am J Psychiatry 151 (1994): 779-80
  12. Staab JP, Yerkes SA, Cheney EM, Clayton AH "Transient SIADH associated with fluoxetine." Am J Psychiatry 147 (1990): 1569-70
  13. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
  14. Ayonrinde OT, Sanfilippo FM "SSRI antidepressants and SIADH." Aust N Z J Psychiatry 31 (1997): 306-7
  15. Kazal LA, Jr Hall DL, Miller LG, Noel ML "Fluoxetine-induced SIADH: a geriatric occurrence?" J Fam Pract 36 (1993): 341-3
  16. "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
  17. Bouman WP, Johnson H, TrescoliSerrano C, Jones RG "Recurrent hyponatremia associated with sertraline and lofepramine." Am J Psychiatry 154 (1997): 580
  18. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.
  19. Blacksten JV, Birt JA "Syndrome of inappropriate secretion of antidiuretic hormone secondary to fluoxetine." Ann Pharmacother 27 (1993): 723-4
  20. Llorente MD, Gorelick M, Silverman MA "Sertraline as the cause of inappropriate antidiuretic hormone secretion." J Clin Psychiatry 55 (1994): 543-4
  21. Girault C, Richard JC, Chevron V, Goulle JP, Droy JM, Bonmarchand G, Leroy J "Syndrome of inappropriate secretion of antidiuretic hormone in two elderly women with elevated serum fluoxetine." J Toxicol Clin Toxicol 35 (1997): 93-5
  22. Bradley ME, Foote EF, Lee EN, Merkle L "Sertraline-associated syndrome of inappropriate antidiuretic hormone: case report and review of the literature." Pharmacotherapy 16 (1996): 680-3
  23. "Selective serotonin reuptake inhibitors and SIADH." Med J Aust 164 (1996): 562
  24. Thornton SL, Resch DS "SIADH associated with sertraline therapy." Am J Psychiatry 152 (1995): 809
  25. Jackson C, Carson W, Markowitz J, Mintzer J "SIADH associated with fluoxetine and sertraline therapy." Am J Psychiatry 152 (1995): 809-10
  26. "Product Information. Lexapro (escitalopram)." Forest Pharmaceuticals, St. Louis, MO.
  27. Vishwanath BM, Navalgund AA, Cusano W, Navalgund KA "Fluoxetine as a cause of SIADH." Am J Psychiatry 148 (1991): 542-3
  28. Goddard C, Paton C "Hyponatraemia associated with paroxetine." BMJ 305 (1992): 1332
  29. "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.
  30. Crews JR, Potts NL, Schreiber J, Lipper S "Hyponatremia in a patient treated with sertraline." Am J Psychiatry 150 (1993): 1564
View all 30 references
Moderate

Fluoxetine (Includes Sarafem) ↔ Renal Dysfunction

Minor Potential Hazard, Low plausibility

Applies to: Renal Dysfunction

Fluoxetine is primarily metabolized by the liver. All but one metabolites are inactive, and they are excreted by the kidney. The clearance of norfluoxetine, the active metabolite, is not dependent on renal function. Dosage adjustments are generally not deemed necessary in patients with impaired renal function, although the clinical significance of possible metabolite accumulation is unknown. Caution may be warranted when fluoxetine therapy is administered in patients with severe renal dysfunction.

References

  1. Aronoff GR, Bergstrom RF, Pottratz ST, Sloan RS, Wolen RL, Lemberger L "Fluoxetine kinetics and protein binding in normal and impaired renal function." Clin Pharmacol Ther 36 (1984): 138-44
  2. "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
Moderate

Ssris (Includes Sarafem) ↔ Weight Loss

Minor Potential Hazard, Moderate plausibility

Applies to: Weight Loss/Failure to Thrive, Malnourished, Anorexia/Feeding Problems

The use of selective serotonin reuptake inhibitors (SSRIs) may occasionally cause significant weight loss, which may be undesirable in patients suffering from anorexia, malnutrition or excessive weight loss. Anorexia may occur in approximately 5% to 10% of patients. Weight change should be monitored during therapy if an SSRI is used in these patients.

References

  1. "Product Information. Celexa (citalopram)." Forest Pharmaceuticals, St. Louis, MO.
  2. Wagner W, Plekkenpol B, Gray TE, Vlaskamp H, Essers H "Review of fluvoxamine safety database." Drugs 43 Suppl 2 (1992): 48-53;disc. 53-4
  3. "Product Information. Zoloft (sertraline)." Roerig Division, New York, NY.
  4. Meyerowitz W, Jaramillo JDC "Sertraline treatment and weight loss." Curr Ther Res Clin Exp 55 (1994): 1176-81
  5. Oliveros SC, Iruela LM, Caballero L, Baca E "Fluoxetine-induced anorexia in a bulimic patient." Am J Psychiatry 149 (1992): 1113-4
  6. Fichtner CG, Braum BG "Hyperphagia and weight loss during fluoxetine treatment." Ann Pharmacother 28 (1994): 1350-2
  7. Vaz FJ, Salcedo MS "Fluoxetine-induced anorexia in a bulimic patient with antecedents of anorexia nervosa." J Clin Psychiatry 55 (1994): 118-9
  8. Fernstrom MH, Massoudi M, Kupfer DJ "Fluvoxamine and weight loss." Biol Psychiatry 24 (1988): 948-9
  9. "Product Information. Luvox (fluvoxamine)." Solvay Pharmaceuticals Inc, Marietta, GA.
  10. "Product Information. Prozac (fluoxetine)." Dista Products Company, Indianapolis, IN.
  11. "Product Information. Paxil (paroxetine)." GlaxoSmithKline, Research Triangle Park, NC.
View all 11 references

Sarafem (fluoxetine) drug Interactions

There are 1091 drug interactions with Sarafem (fluoxetine)

Sarafem (fluoxetine) alcohol/food Interactions

There is 1 alcohol/food interaction with Sarafem (fluoxetine)

Drug Interaction Classification

The classifications below are a general guideline only. It is difficult to determine the relevance of a particular drug interaction to any individual given the large number of variables.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No information available.

Do not stop taking any medications without consulting your healthcare provider.

Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.

Hide